We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+13.16%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$2.29B
AUM Growth
+$308M
Cap. Flow
+$128M
Cap. Flow %
5.6%
Top 10 Hldgs %
38.21%
Holding
106
New
19
Increased
26
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
XPER icon
Xperi
XPER
+$44M
2
NFE icon
New Fortress Energy
NFE
+$40.7M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$39.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29.7M
5
ZYME icon
Zymeworks
ZYME
+$21.2M

Top Sells

Rank Stock Value
1
ADEA icon
Adeia
ADEA
+$101M
2
APO icon
Apollo Global Management
APO
+$44.2M
3
GSM icon
FerroAtlántica
GSM
+$36.1M
4
GPRE icon
Green Plains
GPRE
+$29.8M
5
HTZ icon
Hertz
HTZ
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 27.49%
2 Energy 19.6%
3 Industrials 18.17%
4 Technology 7.38%
5 Financials 7.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FREE
76
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
$4.06M 0.18%
998,363
-2,585,000
-72% -$9.39M
CTMX icon
77
CytomX Therapeutics
CTMX
$760M
$3.85M 0.17%
2,406,449
– –
XOMA
78
DELISTED
Xoma
XOMA
$3.81M 0.17%
206,835
+6,050
+3% +$110K
HOWL icon
79
Werewolf Therapeutics
HOWL
$18.6M
$3.76M 0.16%
1,835,387
+868,508
+90% +$2.27M
ATAI icon
80
AtaiBeckley Inc
ATAI
$2.68B
$3.51M 0.15%
1,319,137
– –
DTIL icon
81
Precision BioSciences
DTIL
$205M
$3.16M 0.14%
88,571
– –
SIOX
82
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.04M 0.13%
7,000,000
– –
CLBT icon
83
Cellebrite
CLBT
$3.8B
$2.74M 0.12%
629,020
– –
TSVT
84
DELISTED
2seventy bio
TSVT
$2.48M 0.11%
265,000
– –
VIRX
85
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.94M 0.08%
1,330,983
+336,182
+34% +$982K
SCTL
86
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.6M 0.07%
1,076,587
– –
NAUT icon
87
Nautilus Biotechnolgy
NAUT
$114M
$1.35M 0.06%
747,607
– –
MRNS
88
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.25M 0.05%
315,277
– –
QSI icon
89
Quantum-Si Incorporated
QSI
$182M
$1.23M 0.05%
672,385
– –
PASG icon
90
Passage Bio
PASG
$14.8M
$1.13M 0.05%
41,105
– –
KORE
91
DELISTED
KORE Group Holdings
KORE
$897K 0.04%
142,450
– –
RNAC icon
92
Cartesian Therapeutics
RNAC
$263M
$815K 0.04%
24,042
– –
ADV icon
93
Advantage Solutions
ADV
$399M
$749K 0.03%
14,403
-61,180
-81% -$3.84M
VIAO
94
DELISTED
VIA optronics AG American Depositary Shares, each representing one-fifth of an Ordinary Share
VIAO
$402K 0.02%
251,855
– –
VINC
95
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$394K 0.02%
19,336
-86,014
-82% -$1.62M
ALEC icon
96
Alector
ALEC
$240M
– –
-900,000
Closed -$8.51M
APO icon
97
Apollo Global Management
APO
$81.9B
– –
-950,343
Closed -$44.2M
AVPT icon
98
AvePoint
AVPT
$2.75B
– –
-1,017,539
Closed -$4.08M
ETNB
99
DELISTED
89bio
ETNB
– –
-989,388
Closed -$5.73M
GPRE icon
100
Green Plains
GPRE
$1.06B
– –
-1,024,165
Closed -$29.8M
1 2 3
4
5

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
LAMI
Longview Asset Management (Illinois) Chicago, Illinois $9.56B AUM 25.94% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $9.56B AUM 21.2% 1-Year Est. Return

Rubric Capital Management (New York)'s Q4 2022 Portfolio in Review

As of Q4 2022, Rubric Capital Management (New York) held 106 positions worth $2.29B, up 16% from $1.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rubric Capital Management (New York) deployed $128M of net new capital in Q4 2022, opening 19 new positions and adding to 26 existing holdings. Its largest new stake was Xperi: 3,843,744 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 23% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Adeia, an estimated $101M trimmed.

  • Rubric Capital Management (New York)'s largest Q4 2022 buy was Xperi: 3,843,744 shares worth $33.1M.
  • Rubric Capital Management (New York) added most to New Fortress Energy in Q4 2022, an estimated $40.7M increase.
  • Rubric Capital Management (New York)'s biggest Q4 2022 reduction was Adeia, cutting an estimated $101M.
  • Rubric Capital Management (New York) fully exited Apollo Global Management in Q4 2022, selling an estimated $44.2M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 38% of its $2.29B portfolio in Q4 2022.
  • Rubric Capital Management (New York) opened 19 new positions and closed 11 in Q4 2022.
  • Rubric Capital Management (New York)'s portfolio value rose 16% quarter-over-quarter to $2.29B.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2022, filed 10 Feb 2023.